![K. David Campagnari](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
K. David Campagnari
President chez Induce Biologics, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
James DeMesa | M | 66 |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada.
Induce Biologics, Inc.
![]() Induce Biologics, Inc. BiotechnologyHealth Technology Induce Biologics, Inc. is a medicine company. The firm is develops bio implants for bone regeneration. It also offers URIST product. The company was founded by Sean Peel and is headquartered in Toronto, Canada. | 23 ans |
Neil Belmore | M | - |
Induce Biologics, Inc.
![]() Induce Biologics, Inc. BiotechnologyHealth Technology Induce Biologics, Inc. is a medicine company. The firm is develops bio implants for bone regeneration. It also offers URIST product. The company was founded by Sean Peel and is headquartered in Toronto, Canada. | - |
Rob R. McEwen | M | - |
Induce Biologics, Inc.
![]() Induce Biologics, Inc. BiotechnologyHealth Technology Induce Biologics, Inc. is a medicine company. The firm is develops bio implants for bone regeneration. It also offers URIST product. The company was founded by Sean Peel and is headquartered in Toronto, Canada. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
AnnKatrin Petersen-Jappelli | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 4 ans |
Bruce A. Schmidt | M | 68 |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 ans |
Steven Gillis | M | 71 |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 12 ans |
Richard Winston DeVries | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | - |
Andrew J. Rae | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 ans |
Paul Brennan | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 1 ans |
C. Robert Cory | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 15 ans |
W. Keith Schilit | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | - |
A. Neil Howell | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | - |
Walter Moos | M | 69 |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 4 ans |
William D. Milligan | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 7 ans |
Jacob J. Clement | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 7 ans |
Alistair Duncan | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 6 ans |
Francis David Duke Scott | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 8 ans |
Doug Johnson | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 ans |
Michael Jeffrey Abrams | M | 68 |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 ans |
Colin R. Mallet | M | 80 |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 13 ans |
Pieter Dorsman | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Canada | 21 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- K. David Campagnari
- Réseau Personnel